CSL Behring LLC
- Address
- 1020 1st Avenue
Sponsor Overview
Specializations
Haemophilia B and Gene Therapy
Research activity includes haemophilia B and Hemophilia B, with a strong emphasis on AAV-based gene therapy, factor IX expression, and long-term control of bleeding risk in adolescent and adult populations.
- Factor IX replacement
- Bleeding prevention
- AAV vector therapy
- Long-term safety follow-up
Clinical interest also extends to neutralizing antibodies and sustained treatment outcomes after gene-based intervention.
Hereditary Angioedema
The sponsor funds studies in hereditary angioedema, Hereditary Angioedema (HAE), and Hereditary angioedema (HAE), focusing on prophylaxis, attack prevention, and treatment switching across adult and pediatric groups.
- C1-inhibitor deficiency
- Angioedema prophylaxis
- Attack prevention
- Pediatric HAE care
Research includes both subcutaneous and intravenous approaches for controlling recurrent swelling episodes.
Sickle Cell Disease and Vaso-occlusive Crisis
Trials in sickle cell disease, Sickle Cell Disease, and sickle cell disease vaso-occlusive crisis examine symptom relief, crisis resolution, and safety in affected adults and adolescents.
- Vaso-occlusive crisis
- Hemolytic complications
- Acute symptom management
- Supportive biologic therapy
Additional work addresses anemia-related complications and disease burden during acute episodes.
Immune-Mediated and Inflammatory Disorders
The portfolio includes acute graft-versus-host disease, dermatomyositis, and related immune-mediated inflammatory disorders, reflecting interest in transplant-associated and systemic autoimmune conditions.
- Graft-versus-host disease
- Dermatomyositis
- Hematopoietic cell transplant
- Immune modulation
These studies focus on disease control in settings where immune dysregulation drives tissue injury and persistent symptoms.
Renal, Pulmonary, and Metabolic Conditions
Research also covers atherosclerotic cardiovascular disease in patients with ESKD, non-cystic fibrosis bronchiectasis, homeostatic iron regulator gene-related hereditary hemochromatosis, and post-COVID-19 postural orthostatic tachycardia syndrome.
- End-stage kidney disease
- Bronchiectasis
- Hereditary hemochromatosis
- Post-COVID dysautonomia
These areas include interest in cardiovascular inflammation, iron overload, and chronic respiratory or autonomic complications.
Sponsored Trials
Data & Insights
This sponsor works with 9 molecules, of which 6 are not being studied by other sponsors.
This sponsor has worked with 322 sites across their trial portfolio.
Therapeutic Focus
- 1.Hemic and Lymphatic Diseases7 trials249 other sponsors
- 2.Congenital, Hereditary, and Neonatal Diseases and Abnormalities4 trials165 other sponsors
- 3.Cardiovascular Diseases2 trials359 other sponsors
- 4.Respiratory Tract Diseases2 trials277 other sponsors
- 5.Immune system processes1 trial65 other sponsors
- 6.Skin and Connective Tissue Diseases1 trial247 other sponsors
Partnered Research Centres
322 centres- Address
- Tvirtoves al. 18, 50169 Kaunas
- Address
- Piazzetta Sant'Andrea delle Dame, 4, 80138 Naples
- Address
- Via Consolare Valeria N 1, 98124 Messina
- Address
- Moelleparkvej 4, 9000 Aalborg
- Address
- Palle Juul-Jensens Boulevard 99, 8200 Aarhus
- Address
- Via Dell' Eremo 9, 23900 Lecco
Want to get in touch with this sponsor?
Send a question and we'll pass it on to CSL Behring LLC.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.